OncoArendi Therapeutics S.A. announced the appointment of Nancy Van Osselaer, Paul van der Horst and Rafal Kaminski to its Supervisory Board. These appointments bring considerable international experience to the Company across all stages of drug development as well as in finance and business development. Dr. Van Osselaer is an experienced global biopharmaceutical professional with over 25 years' experience leading drug development projects at leading pharmaceutical companies.

Nancy currently serves as an independent consultant for her company Why2What, which provides strategic implementation advice to biotech companies. Dr. van der Horst has a strong track record of biotech business development having acted as lead negotiator in over 20 licensing and M&A transactions and raised over $1.3 billion through capital market transactions during his career. Dr. Kaminski has over 20 years' experience in drug discovery, clinical candidate delivery and late stage development alongside global R&D and industry leadership experience.

He was previously the Company's Scientific Officer and a member of its Management Board. Dr. Kaminski will shortly be taking up an executive position as Chief Scientific Officer at Angelini Pharma, the pharmaceutical division of Angelini Industries.